In a recent bid Heat Biologics Inc. [HTBX] faced a contemporary bid of $2.80 yielding a 103.42% incline where 12.93 million shares have exchanged hands over the last week. HTBX amount got a fall by -5.72% or -$0.17 versus $2.97 at the end of the prior session. This change led market cap to move at 201.37M, putting the price 1335.90% below the 52-week high and -34.88% above the 52-week low. The company’s stock has a normal trading capacity of 12.93 million shares while the relative volume is 1.73.

On 22, June 2020, Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35. According to news published on Yahoo Finance, DURHAM, NC / ACCESSWIRE / June 22, 2020 / Heat Biologics, Inc. (“Heat”) (HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that the first patient has been treated in the Company’s first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics’ Pelican Therapeutics subsidiary.

Analyst Birdseye View:

The most recent analyst activity for Heat Biologics Inc. [NASDAQ:HTBX] stock was on January 08, 2016, when it was Initiated with a Buy rating from Noble Financial, which also raised its 12-month price target on the stock to $16. On May 26, 2015, H.C. Wainwright Initiated a Buy rating and boosted its price target on this stock to $13. On September 18, 2013, Aegis Capital Initiated a Buy rating and increased its price target to $36.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.19 and a peak of $4.30. Right now, the middling Wall Street analyst 12-month amount mark is $3.75. At the most recent market close, shares of Heat Biologics Inc. [NASDAQ:HTBX] were valued at $2.80. According to the average price forecast, investors can expect a potential return of -6.67%.


Heat Biologics Inc. [NASDAQ:HTBX] most recently reported quarterly sales of 901.9 million, which represented growth of 28.60%. This publicly-traded organization’s revenue is $84,697 per employee, while its income is -$556,044 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -34.96, -91.28, -85.58 and -87.94 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 12.44 and the whole liability to whole assets at 3.58. It shows enduring liability to the whole principal at 10.72 and enduring liability to assets at 0.03 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 2.55 points at 1st support level, the second support level is making up to 2.13. But as of 1st resistance point, this stock is sitting at 3.24 and at 3.51 for 2nd resistance point.

Heat Biologics Inc. [HTBX] reported its earnings at -$0.11 per share in the fiscal quarter closing of 3/30/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.1/share signifying the difference of -0.01 and -10.00% surprise value. Comparing the previous quarter ending of 12/30/2019, the stated earnings were -$0.1 calling estimates for -$0.14/share with the difference of 0.04 depicting the surprise of 28.60%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Heat Biologics Inc. [NASDAQ:HTBX] is 3.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.75. Now if looking for a valuation of this stock’s amount to sales ratio it’s 5.18 and it’s amount to book ratio is 1.18.